• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Consumer Cyclical·6578.TWO
Share

DaBomb Protein Biotech Corp. Stocks

NT$ 16.35Last Updated 19.10.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

NT$ 36.83M

NT$ 16.35
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

DaBomb Protein Biotech Corp. is a specialized biotechnology enterprise primarily dedicated to developing and commercializing antibiotic replacements for the animal health industry. Its extensive product range includes plant-based proteins such as DaBomb-P (Aqua) and DaBomb-P (Livestock), alongside specific antibiotic alternative solutions like DBT-100 HT and DBT-100 LS. The company also manufactures pet care products, featuring LACTOTIDES HEALTH A+ and Liqui-TIDE bandages. Founded in 2001 and headquartered in Tainan, Taiwan, the firm adopted its current name, DaBomb Protein Biotech Corp., in October 2023, having previously operated as DaBomb Protein Corp.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA, overpriced on P

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

19.10.2026 18:30

Fortune 500, SpaceX, and Data Centers: What Analysts See as the Potential for Brady Stock

19.10.2026 18:09

From Hershey to AbbVie: Goldman Names 23 Defensive Stocks Amid a Tech Sector Sell-off

19.10.2026 16:08

Morning in New York: Looking for a Foothold Ahead of Tech Giants' Earnings Reports

19.10.2026 15:56

After the elections, French markets face a more serious test—the City. What should investors do?

19.10.2026 15:19

An analyst has identified a new driver for Victoria's Secret's stock: weight-loss products

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026